SGLT2 Inhibitor Wows in Chronic Kidney Illness

SGLT2 Inhibitor Wows in Chronic Kidney Illness

In chronic kidney illness (CKD), dapagliflozin (Farxiga) diminished renal events and substantially improved total survival, no topic diabetes train, the DAPA-CKD trial confirmed. The SGLT2 drug diminished by a relative 39% the fundamental endpoint of worsening kidney function (greater than…